Application of Synaptamide in treatment of hyperlipemia

Abstract

The invention discloses an application of Synaptamide in the treatment of hyperlipemia, and relates to a medicine for treating hyperlipemia. In-vivo experiments are carried out in a hyperlipidemia mouse model fed with high-fat diet, and after treatment with Synaptamide, the content of plasma triglyceride is remarkably reduced, and the content of plasma cholesterol is remarkably reduced. Therefore, Synaptamide can be used as a medicine for treating hyperlipemia, it is found for the first time that Synaptamide can effectively reduce the content of triglyceride and cholesterol in blood, and the medicine can effectively prevent and control hyperlipemia so as to reduce the incidence rate of ASCVD, so that a new intervention means is provided for prevention and control of atherosclerosis and related cardiovascular and cerebrovascular diseases.

Description

Technical Field

[0001] The invention relates to application of Synaptamide in treating hyperlipidemia, and belongs to the technical field of biomedicine. Background Art

[0002] Hyperlipidemia (HLP) usually refers to elevated levels of total cholesterol and / or triglycerides in serum, including various dyslipidemias including low high-density lipoprotein cholesterol. Dyslipidemia characterized by high cholesterol levels is an important risk factor for atherosclerotic cardiovascular diseases (ASCVD) such as coronary heart disease. How to effectively prevent and control hyperlipidemia and reduce the incidence of ASCVD has become a major social problem currently faced. Synaptamide, also known as N-docosahexaenoylethanollamine (CASNo.: 162758-94-3), is a metabolite of docosahexaenoic acid (DHA, 22:6n-3). Studies in recent years have shown that Synaptamide plays a regulatory role in neuronal development and brain cognitive function. However, to date, there has been no report on whether Synaptamide can be used to treat hyperlipidemia. Summary of the invention

[0003] The purpose of the present invention is to provide the use of Synaptamide in treating hyperlipidemia.

[0004] In order to achieve the above object, the present invention provides the following technical solutions:

[0005] Use of Synaptamide or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating hyperlipidemia, wherein the chemical structural formula of Synaptamide is as follows:

[0006]

[0007] Preferably, the hyperlipidemia includes hypertriglyceridemia and hypercholesterolemia.

[0008] Preferably, the dosage form of the drug includes injection, tablet, powder, suspension, capsule, pill or syrup.

[0009] Compared with the prior art, the present invention has the following beneficial effects:

[0010] The present invention can significantly reduce the plasma triglyceride content and plasma cholesterol content of hyperlipidemia mice by intraperitoneal injection of Synaptamide; therefore, the present invention is the first to discover that Synaptamide can be used as a therapeutic drug for hyperlipidemia, and the drug can effectively prevent and control hyperlipidemia and thus reduce the incidence of ASCVD. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 : Compared with the control group mice, the plasma triglyceride content of the Synaptamide group mice was significantly reduced.

[0012] Figure 2 : Compared with the control group mice, the plasma cholesterol content of the Synaptamide group mice was significantly reduced. DETAILED DESCRIPTION

[0013] In order to make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.

[0014] The experimental methods in the following examples without specifying specific conditions were carried out according to conventional methods and conditions, or selected according to the product instructions; the materials, reagents, etc. used were conventional commercially available products unless otherwise specified.

[0015] Example

[0016] 1. Experimental Materials and Methods

[0017] 1. Mouse experiment: 8-week-old C57BL / 6 male mice were purchased from Shanghai Slake Experimental Animal Co., Ltd. The feeding and experiments were completed in the Department of Experimental Animal Science, School of Medicine, Shanghai Jiao Tong University. Normal diet feed was purchased from Shanghai Slake Experimental Animal Co., Ltd., item number M01-F, and the ingredients included: 10Kcal% fat, 70Kcal% carbohydrates, and 20Kcal% protein. High-fat diet feed was purchased from Research Diet, USA, item number A06071302, and the ingredients included 60Kcal% fat. Synaptamide was purchased from MedChemExpress, item number: HY-100197. All mice were euthanized after reaching the end point of the experiment. After anticoagulation and centrifugation of whole blood, the supernatant was taken to obtain plasma, which was stored at -80 degrees. In subsequent experiments, it was used to detect the content of plasma triglycerides and cholesterol.

[0018] 2. Plasma triglyceride content detection: The detection was completed according to the instructions of the triglyceride quantitative detection kit provided by Biovision, USA, catalog number K622.

[0019] 3. Plasma cholesterol content detection: The detection was completed according to the instructions of the triglyceride quantitative detection kit provided by Biovision, USA, item number K603.

[0020] 4. Statistical analysis: In this study, all numerical variables were expressed as mean ± standard error, and the variables between the two groups were compared using a two-tailed Student-t test. When P < 0.05, the two groups were considered to have statistically significant differences. * indicates P < 0.05, ** indicates P < 0.01, and *** indicates P < 0.001.

[0021] (II) Implementation plan and results

[0022] Feeding C57BL / 6 mice with a high-fat diet is a common method for constructing an animal model of hyperlipidemia. In this example, 12 6-week-old C57BL / 6 male mice were fed a normal diet for 2 weeks to adapt to the breeding environment. They were then fed a high-fat diet for 10 weeks and randomly divided into two groups, each with 6 mice, and given intraperitoneal injections of Synaptamide (5 mg / kg) or a control solvent once a day. After two weeks of continuous injection, the mice were euthanized and plasma was taken for testing. The results showed that compared with the control group of mice, the plasma triglyceride content of the Synaptamide group mice was significantly reduced ( Figure 1 ), plasma cholesterol levels were significantly reduced ( Figure 2 ). The above results confirm that Synaptamide can effectively improve hyperlipidemia.

[0023] In summary, the present invention has found through animal in vivo experiments that Synaptamide can significantly reduce plasma triglyceride content and plasma cholesterol content. Therefore, Synaptamide shows good application prospects as a therapeutic drug for hyperlipidemia, and helps prevent and control the occurrence of cardiovascular and cerebrovascular diseases such as atherosclerosis, coronary heart disease, and stroke.

[0024] The above description is only a preferred embodiment of the present invention and is not any formal or substantial limitation of the present invention. It should be pointed out that a person skilled in the art can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.

Claims

1. Use of Synaptamide or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating hyperlipidemia, wherein the chemical structural formula of Synaptamide is as follows:

2. The use according to claim 1, characterized in that The drug comprises a medically acceptable carrier and an effective amount of an active ingredient, wherein the active ingredient is Synaptamide or a pharmaceutically acceptable salt thereof.

3. The use according to claim 1, characterized in that The hyperlipidemia includes hypertriglyceridemia and hypercholesterolemia.

4. The use according to claims 1 to 3, characterized in that: The dosage form of the drug includes injection, tablet, powder, suspension, capsule, pill or syrup.

Images